PDE5A and cancer: Interestingly, a preclinical study [87] using naïve mice showed a sexually dimorphic immune modulation of PDE5 inhibitors, a class of drugs currently tested to downregulate MDSC action in cancer patients [88,89]: in naïve mice PDE5 seemed to reduce NK and memory T cells in male, while increasing these subsets in female.